Rapid Communication
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor

https://doi.org/10.1016/S0014-2999(97)01160-6Get rights and content

Abstract

The effects of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-yl]-(1-napthalenyl)methanone mesylate (WIN 55,212-2) and N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-pyrazole-carboxamide (SR141716A) on guanosine-5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding to membranes isolated from human cannabinoid CB1 receptor-transfected Chinese hamster ovary (CHO) cells were examined. WIN 55,212-2 stimulated [35S]GTPγS binding 76.3% above basal levels whereas SR141716A produced a 22.3% decrease in basal [35S]GTPγS binding. These findings demonstrate that WIN 55,212-2 is an agonist and SR141716A is an inverse agonist in this system.

Section snippets

Acknowledgements

This work was supported in part by grants from the Arizona Disease Control Research Commission and the National Institute of Drug Abuse.

References (6)

There are more references available in the full text version of this article.

Cited by (241)

  • Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα<inf>i/o</inf> protein inhibitor

    2018, Neuropharmacology
    Citation Excerpt :

    The inhibitory effect of rimonabant was observed at concentrations of GDP and NaCl that allow a constant and significant reduction in basal [35S]GTPγS, as previously reported (Sim-Selley et al., 2001). However, in contrast to previous studies (Landsman et al., 1997; MacLennan et al., 1998; Howlett et al., 2011), rimonabant at 10 and 100 nM concentrations failed to inhibit basal [35S]GTPγS binding (100.3% ± 2 and 93% ± 5 over basal activity, respectively). The effect of rimonabant on the stimulation of [35S]GTPγS binding by baclofen and the D2 receptor agonist quinpirole was measured in rat and mouse cortical membranes.

  • Peripheral modulation of the endocannabinoid system in metabolic disease

    2018, Drug Discovery Today
    Citation Excerpt :

    Furthermore, CB1-deficient mice have increased energy expenditure [39]; and even following consumption of a high-fat diet (HFD) (49% of energy as fat) CB1-deficient mice do not become obese [38]. Rimonabant, the most widely studied antagonist, has been shown to act as a CB1 antagonist and inverse agonist [40,41]. Rimonabant was developed and marketed for the treatment of obesity but was withdrawn from the market in 2008 owing to severe psychological side effects.

  • Signaling and Regulation of the Cannabinoid CB1 Receptor

    2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment
View all citing articles on Scopus
View full text